LP
INMB icon

LMR Partners’s INmune Bio INMB Stock Holding History

LMR Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Hold
16,600
– – ﹤0.01% 1423
2026
Q1 		$18.8K Hold
16,600
– – ﹤0.01% 1350
2025
Q4 		$25.9K Hold
16,600
– – ﹤0.01% 1402
2025
Q3 		$34.4K Buy
+16,600
New +$38K ﹤0.01% 1329

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LMR Partners's INMB Position: Q2 2026 in Review

LMR Partners held its INmune Bio (INMB) position steady in Q2 2026 at 16,600 shares worth $27.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1423.

LMR Partners first reported a position in INMB in Q3 2025 and has held it in 4 quarters since. The position peaked at $34.4K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • LMR Partners held 16,600 shares of INmune Bio worth $27.1K as of Q2 2026.
  • LMR Partners left its INmune Bio share count unchanged in Q2 2026.
  • INmune Bio made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1423 holding.
  • LMR Partners first reported a position in INmune Bio in Q3 2025 and has held it in 4 quarters since.
  • LMR Partners's INmune Bio position peaked at $34.4K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.